| Maryam Gul, MD | |
|
2050 S Euclid St, Anaheim, CA 92802-3111 | |
| (714) 883-7180 | |
| Not Available |
| Full Name | Maryam Gul |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 12 Years |
| Location | 2050 S Euclid St, Anaheim, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497015192 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | A149391 (California) | Primary |
| Entity Name | Precision Rheumatology Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558991596 PECOS PAC ID: 4486084688 Enrollment ID: O20200429003101 |
News Archive
The Intellectual Property and Science business of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today released a new study in recognition of World Hepatitis Day on Life Sciences Connect, a blog exploring the latest news and trends in Life Sciences and updates on the drug pipeline identifying multiple treatments in development that may serve as potential alternatives to Gilead's Sovaldi, currently priced in the United States at $84,000 for 12 weeks of treatment - $1000 per pill.
CardioFocus, a venture capital-backed medical device company developing technology to treat cardiac disorders, has secured $5M in debt financing from Silicon Valley Bank, financial partner to technology and life science companies of all sizes worldwide. CardioFocus will use the new financing to initiate its pivotal trial in the United States and to expand the commercialization of its products in Europe.
"The problem is that U.N. agencies, USAID, its European counterparts, and NGOs almost all think that to get attention for a given crisis, they must use apocalyptic language and err on the side of overestimating the death, damage, and displacement that has been caused," author David Rieff writes in a Foreign Policy opinion piece.
The hepatitis C virus (HCV) has a previously unrecognized tactic to outwit antiviral responses and sustain a long-term infection. It also turns out that some people are genetically equipped with a strong countermeasure to the virus' attempt to weaken the attack on it.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Maryam Gul, MD 2347 Mangular Ave, Corona, CA 92882-5789 Ph: () - | Maryam Gul, MD 2050 S Euclid St, Anaheim, CA 92802-3111 Ph: (714) 883-7180 |
News Archive
The Intellectual Property and Science business of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today released a new study in recognition of World Hepatitis Day on Life Sciences Connect, a blog exploring the latest news and trends in Life Sciences and updates on the drug pipeline identifying multiple treatments in development that may serve as potential alternatives to Gilead's Sovaldi, currently priced in the United States at $84,000 for 12 weeks of treatment - $1000 per pill.
CardioFocus, a venture capital-backed medical device company developing technology to treat cardiac disorders, has secured $5M in debt financing from Silicon Valley Bank, financial partner to technology and life science companies of all sizes worldwide. CardioFocus will use the new financing to initiate its pivotal trial in the United States and to expand the commercialization of its products in Europe.
"The problem is that U.N. agencies, USAID, its European counterparts, and NGOs almost all think that to get attention for a given crisis, they must use apocalyptic language and err on the side of overestimating the death, damage, and displacement that has been caused," author David Rieff writes in a Foreign Policy opinion piece.
The hepatitis C virus (HCV) has a previously unrecognized tactic to outwit antiviral responses and sustain a long-term infection. It also turns out that some people are genetically equipped with a strong countermeasure to the virus' attempt to weaken the attack on it.
› Verified 3 days ago
Richard Eugene Hughes, M.D. Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 1300 N. Kraemer Blvd., Anaheim, CA 92806 Phone: 714-630-6363 Fax: 714-630-1921 | |
Michael Salvaggio, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: Kaiser Permanente-orange County, 411 N. Lakeview Ave, Anaheim, CA 92807 Phone: 714-279-4594 | |
Abraham Harn, DO Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1211 W La Palma Ave Ste 404, Anaheim, CA 92801 Phone: 714-772-8282 Fax: 714-772-6493 | |
Aleem A Syed, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1211 W La Palma Ave, Suite 702, Anaheim, CA 92801 Phone: 714-533-0300 Fax: 714-533-0700 | |
Dr. Jagminder Singh Bhalla, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1781 W Romneya Dr, Ste C, Anaheim, CA 92801 Phone: 714-956-3160 Fax: 714-956-1188 | |
Dr. Ashley E. Mires, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1211 W La Palma Ave, #207, Anaheim, CA 92801 Phone: 714-772-8282 Fax: 714-772-6493 | |
Hyon Chong Seo, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 441 N Lakeview Ave, Anaheim, CA 92807 Phone: 888-988-2800 |